DOTATATE PET for Meningioma Radiation Planning

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-06-30

Study Completion Date

2027-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

68Ga-DOTATATE-based radionuclides are a novel modality in the diagnosis and treatment of central nervous system meningioma. DOTATATE is a ligand for the SSTR (somatostatin receptor), which is expressed in meningioma but not in normal brain or bone. It is also more effective than MRI in delineating tumor, which is the current imaging standard for assessing meningioma. For radiation planning, it can help to reduce the risk of geometrical miss, identify area that require dose-escalation, and reduce dose to normal tissue. The purpose of the study is to compare the radiation therapy (RT) contouring and planning for meningioma with and without the use of 68Ga-DOTATATE-PET

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Concordance and Accuracy of MRI in the Detection of Meningiomas: Optimizing Sequences With Low Doses of Gadolinium

NCT04113395

Meningioma

COMPLETED

Using a Novel Functional MRI Technique to Evaluate for Neurotoxicity

NCT03342586

Central Nervous System Lymphoma

COMPLETED

MRI Biomarkers for Radiation-Induced Neurocognitive Decline Following SRS of Newly Diagnosed Brain Mets

NCT04073966

Brain Metastases Neurocognitive Deficit White Matter Alterations +1 more

RECRUITING

Contrast Enhanced MRI of the CNS - Patients With Known Cerebral Neoplastic Lesions.

NCT00764387

Neoplastic CNS Lesions

COMPLETED PHASE4

PET Imaging of Neuroinflammation in Neurodegenerative Diseases Via a Novel Translocator Protein (TSPO) Radioligand

NCT03958630

Dementia

TERMINATED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Meningioma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

DOTATATE-PET scan

Group Type EXPERIMENTAL

DOTATATE-PET scan

Intervention Type DIAGNOSTIC_TEST

DOTATATE tracer PET scan for meningioma

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

DOTATATE-PET scan

DOTATATE tracer PET scan for meningioma

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years old
* Able and willing to comply with the study procedures
* Intact meningioma requiring definitive radiation
* Post-operative meningioma requiring adjuvant radiation
* No prior radiation therapy or medical therapy directed at the tumour